New combo shows promise for Hard-to-Treat gut cancer
NCT ID NCT04258956
First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 18 times
Summary
This study tested a combination of two drugs, avelumab and axitinib, in 58 adults with advanced gastrointestinal stromal tumor (GIST) that had worsened after standard treatments like imatinib and sunitinib. The goal was to see if the combination could stop or slow cancer growth for at least 3 months. The approach uses immunotherapy and a targeted drug to control the disease, not cure it.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROINTESTINAL STROMAL TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Maria Sklodowska-Curie National Research Institue of Oncology
Warsaw, 02-781, Poland
Conditions
Explore the condition pages connected to this study.